Developing EBP Inhibitors to treat:

Colorectal Cancer & Multiple Sclerosis

Compelling activity has been demonstrated with our clinical candidate, (S)-TASIN-15, in animal colorectal cancer models leveraging synthetic lethality.

Human Phase 1 Trial in colorectal cancer in 2024
Preclinical development of a chemically distinct TASIN in demyelinating diseases in 2024

0

people a year die from
colorectal cancer worldwide.

#2

Colorectal cancer is the 2nd leading cause of cancer deaths worldwide.

0

deaths annually in the U.S. despite newer drugs (EGFR, VEGF, PD-L1 inhibitors)

 Globocan 2020 cancer statistics

Our Drug Platforms:
TASIN in Oncology & Neurology

TASIN in Colorectal Cancer (CRC) is lethal for mutated APC (APCmut) cancer cells, while having minimal effect on normal cells.

TASIN in multiple sclerosis (MS) directly binds and inhibits a target gaining much interest in the Pharma industry, emopamil binding protein (EBP), which results in the formation of myelin around nerve cells.

TASIN has shown to be highly potent, resulting in significant inhibition of CRC tumor growth, with no apparent toxicity to normal cells.

We have confirmatory data that TASIN binds to EBP using multiple approaches including CRISPR technology.

Learn More

Overview of Therapeutic Programs

TASIN in Oncology | CRC

  • Potent, small molecule drugs licensed from The University of Texas Southwestern Medical Center.

  • Selective for APCmut, an important and highly prevalent marker of colorectal cancer.

  • MOA via inhibition of EBP, a key intermediate enzyme in cholesterol biosynthesis.

  • Strong preclinical POC

  • Clinical candidate declared, (S)-TASIN-15.

  • Current status: GLP Toxicology completed,            IND preparation in progress.

  • Represents a unique and large commercial opportunity.

  • Another Pharma Co’s. EBP inhibitor drug is currently under investigation in a Phase 1 trial for patients with brain cancer (Glioblastoma Multiforme, Gliomas)

TASIN in Neurology | MS

  • Growing recognition of emopamil binding protein (EBP) as an important target in demyelinating diseases, such as multiple sclerosis. 

  • Clear interest from Big Pharma companies as EBP has been validated as a drugable target in MS.

  • A publication in Nature showed that Barricade’s compounds restored myelin in vitro. 

  • Initial animal proof-of-concept study indicated presence of early biomarkers for remyelination.

  • Barricade intends to rapidly advance a second-generation TASIN compound for this high-value indication.

  • Current status: Plan to initiate lead compound selection. The TASIN analog selected will be chemically distinct from (S)-TASIN-15.

"We expect (S)-TASIN-15 to be in the clinic for patients with APCmut CRC in 2024, with human proof of concept in 2025. There are also some very interesting opportunities for TASIN in demyelinating diseases — such as multiple sclerosis (MS). We have demonstrated biological effects of our TASINs in a animal model of MS and are planning to identify TASIN candidates to advance into preclinical development.
Interestingly, other Pharma Co.'s are now pursuing EBP as a drugable target in both cancer and MS indications. We’re currently seeking investors to reach key value inflection points."

Neil Thapar

CEO & Chief Scientific Officer